Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain‐like lesion during the COVID‐19 pandemic.

Chilblain-like lesions (CLL) have been extensively reported during coronavirus disease-19 (COVID-19) pandemic in March-April 2020.1 While the link between these lesions and severe acute respiratory coronavirus 2 (SARS-CoV-2) is still unclear,2 emerging evidence of "long COVID", with extra-cutaneous COVID-19 symptoms persisting over 60 days, is reported.3The aim of this study was to assess the evolution of the CLL overtime. Our data emphasize that a majority of patients, who experienced CLL during the first wave of COVID-19 pandemic, developed relapsing CLL with or without other persistent cutaneous manifestations. 7,8 First, assuming that our patients were infected by SARS-CoV-2, we demonstrate a high prevalence of disabling persistent extra-cutaneous and cutaneous symptoms, classifying them as "extra-cutaneous long COVID" in 28% and "cutaneous long COVID" in 67% of cases. [Extracted from the article]